Introduction
Levetiracetam (LEV) is one of the latest antiepileptic drugs (AED) available on the market for treating drug resistant partial epilepsy in adults. 1 Mechanisms underlying its antiepileptic activity are still incompletely understood. The pharmacokinetic profile of LEV, which is characterised by its rapid and almost complete absorption after oral administration, linear pharmacokinetics, minimal protein binding and predominantly renal excretion, makes the drug a good option for the treatment of paediatric patients. 2 However, although double-blind placebo-controlled clinical trials and uncontrolled Seizure (2005) Summary The aim of this multicentric, prospective and uncontrolled study was to evaluate the efficacy and safety of levetiracetam in 110 children with refractory epilepsy, of whom 21 were less than 4 years old. After a median follow-up period of 7 months, levetiracetam administration was effective (responders with >50% decrease in seizure frequency) in 39% of children, of whom 10 (9%) became seizure-free. The efficacy was higher in patients with localization-related epilepsy (58% of responders) than in those with generalized epilepsy (37% of responders). Levetiracetam was well tolerated. The main side effects of somnolence and irritability occurred in 14% of patients. In one patient acute choreoathetosis occurred after few doses of levetiracetam. Overall, the adverse effects were not severe. Children younger than 4 years were particularly tolerant. In conclusion, the present study confirms that levetiracetam is effective and well tolerated as an add-on treatment in children with refractory epilepsy. Our preliminary data also indicate that levetiracetam may be a valid therapeutic option for epilepsy in infants and young children. studies have demonstrated the efficacy of LEV in adults, [3] [4] [5] [6] [7] [8] [9] [10] only a few studies have examined the usefulness of this drug in treating childhood epilepsy. 10 In particular, with the exception of a few reports, [11] [12] [13] [14] [15] [16] [17] [18] it is still necessary to establish the efficacy of LEV for epilepsy syndromes. Indeed, most studies have evaluated the efficacy of LEV in relation to seizure type. 11 Here we report on a multicentric, prospective, uncontrolled study undertaken to acquire further information about efficacy and toleration of LEV in a paediatric population with refractory epilepsy syndromes.
Patients and methods

Study design
This was an open, multicentric, prospective, pragmatic study reflecting normal clinical practice when the decision is made to add a new antiepileptic drug to those already prescribed for a child with refractory seizures. Seizure frequencies, type and duration were recorded by parents and caregivers over a 6-month period before starting treatment with LEV. The drug was administered at a daily dose of 5 mg/ kg, given in two or three equal doses per day, with the dose increasing every week up to a maximum of 60 mg/kg per day. If adverse reactions occurred, the titration phase was extended on the basis of clinical information. In all patients, general clinical neurological examinations and EEGs were performed at inclusion and after a minimum of 8 weeks. Thereafter, neurological examination and EEGs together with complete peripheral blood counts, urinary analysis and measurement of blood creatinine, alanine and aspartate aminotransferase levels were performed every 3 months. However, in three patients a follow-up period of 2 months only was available.
Patients
From January 2001 to December 2003, 110 children (52 girls and 60 boys) under 16 years receiving LEV were recruited from five centres in Italy. The mean age at enrolment was 7.7 years (range 6 months to 15.9 years). Of the 110 patients, 21 (19%) were less than 4 years old. Patients with progressive neurological disorders were excluded from the study. Family and personal histories were taken and neurological examinations performed on all patients. Electroencephalograms (EEGs) were recorded during wakefulness, spontaneous sleep and arousal, with hyperventilation and photic stimulation in subjects that gave sufficient collaboration. Long-term video EEG was performed when it was considered useful for classifying the type of epilepsy. All patients underwent imaging studies with brain magnetic resonance imaging (MRI). Biochemical analyses, chromosomal investigations and screening for metabolic disorders were carried out in all patients. Seizure types and epilepsy syndromes were classified in accordance with the International League Against Epilepsy (ILAE) classifications. [19] [20] [21] Intelligence quotient (IQ) was evaluated by the Brunet-Lézine test and WISC-R, according to the patient's age. Mental retardation was present in 81 patients (74%) and considered severe in 45, moderate in 19, and mild in 17. Median seizure frequency was 22 seizures/month (range 4-129). Mean age at the first seizure was 2.6 years (range 0.5-13 years). The mean duration of epileptic history was 6.4 years (range 0.6-15 years). Epilepsy was symptomatic in 43 patients (39%) and cryptogenic in 67 (61%) ( Table 1 ). In 28 patients (25%), partial seizures had a secondary generalization. Epilepsy was related to localization (LRE) in 53 patients (48%), generalized in 45 (41%) and unclassifiable in 12 (11%) ( Table 2 ). Specifically, patients less than 4 years old were affected by LRE 13 and generalized epilepsy. 8 Informed consent for LEV administration was obtained from the parents. A mean of seven (range 2-12) AEDs were tried before introducing LEV treatment. The number of AEDs administered when LEV treatment began ranged from one to five (median two); 29 patients (26%) received one AED, 57 patients (52%) two AEDs, 18 (16%) three AEDs and six (5%) more than three AEDs. Drugs administered at the start of LEV therapy included valproate (46%), carbamazepine (37%), vigabatrin (27%), topiramate (26.5%), clonazepam (24.5%), lamotrigine (18.5%), chlormethyldiazepam (9%) and phenobarbital (5%).
Response
Compared with baseline seizure frequency and severity, the response to LEV treatment was classified as: complete cessation (100% seizure control); very good (seizure frequency decreased by 50-99%); minimal (seizure reduction to less than 50% with minimal change in seizure severity); unmodified (seizure reduction less than 20%) or worse (increase in seizure frequency). We defined responders those patients who at the last follow-up visit had more than 50% reduction in seizure frequency during a minimum period of 8 weeks. Efficacy was evaluated in accordance with the type of epilepsy syndrome and age before LEV treatment. The presence of adverse events was obtained from parents at each control.
Statistical evaluations
Levels of significance were calculated using Fisher's exact test, ANOVA and the two-tailed Wilcoxon rank sum test for non-parametric data.
Results
Clinical follow-up ranged from 2 to 20 months (median 7.6). LEV dosages varied from 10 to 60 mg/kg per day (median 38 AE 4.1).
Efficacy
Forty-five patients (41%) remained on LEV therapy at the latest follow-up. In the remaining 65 patients, administration of the drug was tapered off because of inefficacy. Specifically, 10 children (9%) became seizure-free, 33 (30%) had a seizure reduction of more than 50%, and 27 (24.5%) had a minimal seizure reduction. In a further 28 patients (25%) seizure frequency remained unchanged, whereas 12 (11%) experienced an increase in seizure frequency. Therefore, 43 patients (39%) were considered positive responders in that they had a greater than 50% reduction in seizure frequency. In two patients, LEV therapy was continued because they became more alert. In relation to the type of epilepsy, LEV appeared more effective in LRE (58% of responders) than in generalized epilepsy (37% of responders). Among patients with LRE, the highest responder rates were in patients with cryptogenic partial seizures (Table 2) . Of the patients with generalized epilepsy, responders were observed in the group exhibiting myoclonic-astatic epilepsy (4/6), generalized symptomatic epilepsy (3/11), generalized cryptogenic epilepsy (2/4), Dravet syndrome (2/ 6), Lennox-Gastaut syndrome (2/8), and infantile spasms (1/5). Two out of three patients with startle epilepsy were responsive to LEV. Two responders (14%) were also observed among the patients having an unclassifiable epilepsy syndrome (Table 2 ). In two patients affected by localization-related epilepsy, LEV monotherapy was considered successful because one was seizure-free after 6 months and the other after 9 months. In a further 24 children (22%), one or more concomitant drugs were tapered off or the doses reduced without affecting seizure frequency. Patients with a short history of epilepsy (less than 3 years) were more likely to become responders than were those whose epilepsy history was more than 3 years (P = 0.049).
Patients younger than 4 years had a higher proportion of responders compared with older patients (57 and 35%, respectively). Specifically, eight patients in this group with LRE (61%) and four (50%) with generalized epilepsy could be classified as responders (Fig. 1) . However, the population size was too small for statistical analysis.
Safety
Adverse reactions occurred in 16 patients (14% of the total entering the study). The most frequently 250 S. Grosso et al. reported treatment-related side effects were drowsiness 12 and nervousness. 3 In two patients, treatment was discontinued because of adverse side effects. Another patient, who had been seizure-free after a few days of LEV treatment (5 mg/kg per day), developed severe acute choreoatethosis, which forced us to taper off the drug. After a few days, a second attempt at LEV introduction was again followed by a relapse of choreoatethosis. LEV was therefore completely suspended and the adverse reaction disappeared. However, when considered over all patients, the side effects were mild in severity. Moreover, in 19 patients (17%), LEV was reported to have beneficial effects in addition to seizure reduction. These patients became ''better behaved'' and demonstrated increased levels of concentration. There were no significant anomalies in the laboratory results of liver function, renal function or haematological criteria.
Discussion
Controlled and open-label studies have demonstrated the efficacy of LEV for a wide range of seizures and epilepsies. LEV has been shown to be effective in children and adults with partial epilepsy. 3, 4, [6] [7] [8] [9] [11] [12] [13] In this context, Glauser et al. found that 52.5% of paediatric patients with partial seizures were responsive to LEV, with more than 50% showing seizure reduction. 12, 13 LEV was also effective in three patients with BECTS. 22 Although anecdotal data has demonstrated LEV efficacy in generalized epilepsy in childhood, most studies have evaluated LEV efficacy in refractory epilepsy syndromes, including children suffering from both generalized and partial epilepsy. In a retrospective open study, Herranz et al. found responders (those with more than 50% seizure frequency reduction) in 43 (65%) of children with both focal and generalized seizures. 14, 15 Lower responder rates (47%) were found by Lagae et al. in open-label add-on study that included 21 children affected by highly refractory epilepsy 11 and by Wheless and Ng who observed a 33.3% responder rate in 39 children with refractory epilepsy. 16 LEV has been effective in Lennox-Gastaut syndrome, in which the drug was found to be effective against myoclonic seizures and tonic-clonic seizures rather than atypical absences. 11, 17 Lagae et al. have also underlined the positive effect of LEV on myoclonic seizures. 11 Anecdotal data reported LEV effectiveness in patients with Landau-Kleffner syndrome 23 and CSWS 24 as well as in some non-epileptic disorders such as spinal myoclonus. 25 Moreover, LEV has been shown to reduce hyperactivity, impulsivity, mood instability and aggression in autistic children. 26 The present study only included patients with refractory epilepsy. All patients were under several therapeutic regimens when LEV treatment was begun. According to Lagae et al., the cardinal goal of add-on treatment in such patients is not for them to be seizure-free, which remains difficult, but to improve their quality of life by decreasing seizure frequency as much as possible while limiting adverse reactions. 11 In the present study, LEV efficacy was evaluated in relation to epilepsy syndromes rather than to seizure types. Indeed, it is known that the same type of seizure may be more or less responsive to an AED in accordance with the epilepsy syndrome in which it occurs, and that this is particularly true in children, who may be affected by a wide spectrum of epileptic syndromes. 27 In summary, 39% of patients had a more than 50% reduction in seizure frequency after a median follow-up period of 7 months. The percentage of responders was lower than that reported by Herranz 14, 15 and by Lagae et al., 11 but was in agreement with that reported by Wheless and Ng. 16 As in the previous studies, we observed a higher responder rate among patients with LRE (58% of responders) than in those affected by generalized epilepsy (37% of responders). In particular, four out of six with myoclonic-astatic epilepsy and two out of eight patients with Lennox-Gastaut were responders. In contrast, only one patient among five with infantile spasms, showed a significant reduction in seizure frequency. However, because all the patients had very refractive symptomatic infantile spasms, we believe that further investigations are needed to establish the real efficacy of LEV for this epilepsy syndrome. It is interEfficacy and safety of levetiracetam: An add-on trial in children with refractory epilepsy 251 Figure 1 Comparison of responsiveness by epilepsy type and patient age (n = 98). On the left are reported patients aged less than 4 years, on the right the older ones. Responders: patients with seizure frequency decreased by 50-100%; no responders: patients with minimal/unmodified variation of seizure frequency; LRE: localization related epilepsy.
esting to note the effectiveness of LEV in the two patients with startle epilepsy, one of whom had been seizure-free for 3 months at follow-up. In general terms, we noted that LEV was more effective in children who had a short history of epilepsy (less than 3 years) than in those with a longer history.
In the present study, we have also evaluated LEV efficacy in children less than 4 years old. There are few data available in the literature on the efficacy and tolerability of LEV in such a population. Our preliminary data suggest that LEV may be effective in controlling epilepsy in infants and young children. In fact, although it was not possible to perform a statistical analysis, responder rates were higher in younger than in older children. Of course, these findings need to be confirmed by further clinical studies.
As in a previous clinical investigation, 11, 16 we also observed that the effect of LEV may be seen in some patients during the first weeks after starting the drug. Indeed, four children became seizure-free after a mean period of 18 days at a mean dosage of 14 mg/kg per day. All of them were affected by cryptogenic LRE. This phenomenon was not observed in children with generalized epilepsy.
With regard to safety, LEV has been reported to be a well-tolerated drug. Adverse reactions, mainly represented by headache, infection, somnolence and anorexia, have been reported, with the incidence varying from 10 12,13 to 19%. 11 Acute psychosis has also been reported. 14, [28] [29] [30] It seems that side effects occur chiefly in those patients taking high LEV doses (>40 mg/kg per day). 11, 14 In the present study, side effects such as somnolence and irritability were observed in 16 patients (14%). However, acute choreoatethosis, which has never been described before, occurred in one patient, forcing us to taper-off the drug in spite of complete seizure control. LEV was also discontinued in two other patients suffering from drowsiness and irritability. However, when globally evaluated, adverse reactions were considered mild in severity and transient. It is interesting that, with the exception of the patient showing acute choreoathetosis, no child of less than 4 years showed severe side effects related to LEV therapy. This seems to indicate that the drug is safe in young children and infants.
Conclusion
The present study demonstrated that LEV may be effective in a wide range of refractory epilepsy syndromes, even when administered before the age of 4 years. Therefore, although comparative studies of other new AEDs used as add-ons are necessary, we believe that LEV may be considered a valid and safe therapeutic option in children with refractory epilepsy syndromes.
